The San Sebastian-based company Quimatryx designs chemical compounds with the aim of turning them into drugs. They have created a first compound against cancer that has already been approved by the Chinese regulatory agency to begin testing in humans. The second, intended for neurological diseases, is in the preclinical phase, and the goal is to … Read more
El 30 de octubre Quimatryx participó en el Simposio ALS-ArrasatELA organizado por la Asociación dalecandELA On October 30, we had the honor of presenting, alongside Eneko Aldaba, our R&D Director, the positive data on our compound QTX153 against ALS at the Arrasate ELA-ALS symposium. We would like to give special thanks to the Dale Candela … Read more
After years of cutting-edge research in epigenetic regulation, Quimatryx announces that the Chinese National Medical Products Administration (NMPA) has approved its Clinical Trial Application (CTA) for QTX125, a first-in-class, highly selective HDAC6 inhibitor, to begin Phase I clinical trials in patients with advanced solid and hematologic tumors. QTX125 is a pioneering small molecule designed to … Read more
Quimatryx has reached a strategic partnership with the Chinese company HiDiamond worth up to $92 million to accelerate the development of its QTX125, an HDAC6 inhibitor anti-cancer compound. Under this agreement, HiDiamond will be responsible for conducting the full regulatory preclinical development and for submitting the application to the Chinese drug regulatory authorities to initiate … Read more